The scientific community is carefully watching progress of Trontinemab, a investigational antibody showing encouraging results in preliminary clinical studies . Trontinemab targets toxic tau , a significant hallmark of the condition, believed to be more linked to cognitive deterioration than the amyloid plaques that often received primary focus . W